CTSB and hepatocellular carcinoma: Indeed, co-treatment of HCC cells with the JNK inhibitor SP600125 and the lysosomotropic agent GPN strongly reduces cellular acidification, which mainly depends on the lysosomes, and promotes the appearance of galectin 3 puncta and cathepsin B in the cytosol, both indicator of lysosomal damage.